Pathstone Family Office’s China Pharma Holdings CPHI Stock Holding History

Pathstone Family Office’s Portfolio CPHI Stock Details CPHI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-17	Closed	-$3K	–	322
2014 Q2	$3K	Hold	17	–	–	0.01%	122
2014 Q1	$4K	Hold	17	–	–	0.01%	134
2013 Q4	$3K	Buy	+17	New	+$2.86K	0.01%	178
2013 Q3	–	Sell	-17	Closed	-$2K	–	324
2013 Q2	$2K	Buy	+17	New	+$1.98K	﹤0.01%	333

Other funds holding CPHI

PAM

Pope Asset Management Memphis, Tennessee $162M AUM

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Glenhill Advisors New York $6.94M AUM 24.62% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Pathstone Family Office's CPHI Position: Q3 2014 in Review

Pathstone Family Office sold out of China Pharma Holdings (CPHI) in Q3 2014, closing a stake of 17 shares — an estimated $3K sold.

Pathstone Family Office first reported a position in CPHI in Q2 2013 and held it in 4 quarters. The position peaked at $4K in Q1 2014. 5 funds tracked by Wall St. Rank hold CPHI as of Q3 2014.

Pathstone Family Office reported no remaining China Pharma Holdings position as of Q3 2014 after selling out during the quarter.
Pathstone Family Office sold 17 China Pharma Holdings shares in Q3 2014, an estimated $3K.
Pathstone Family Office first reported a position in China Pharma Holdings in Q2 2013 and held it in 4 quarters.
Pathstone Family Office's China Pharma Holdings position peaked at $4K in Q1 2014.
5 funds tracked by Wall St. Rank held China Pharma Holdings as of Q3 2014.

Based on Pathstone Family Office's 13F filing for Q3 2014, filed 12 Nov 2014.